Category - Markets

BTIG upgraded Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) to “buy” from “neutral,” with a $14 price target, after the company closed a $17.5-million stock offering. The stock closed at $8 on Nov. 19. Analyst Dr...

H.C. Wainwright analyst Joseph Pantginis assumed coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and price target of $18.50. The stock closed at $4.52 on Nov. 19. Caladrius is developing two...

Mackie Research raised its price target for Bellus Health (TSX:BLU) to $2.20 from $1 after the company reported Phase 1 top-line results of BLU-5937 for the treatment of chronic cough. In the study, BLU-5937...

Leerink Partners launched coverage of Assembly Biosciences (NASDAQ:ASMB) with an “outperform” rating and $45 price target. The stock closed at $24.67 on Nov. 16. “Our valuation and rating are based on our probability...

A.G.P./ Alliance Global Partners raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to 65 cents from 45 cents after the company’s third quarter results exceeded forecasts. The stock closed at 40 cents on...

Leerink Partners initiated coverage of AC Immune (NASDAQ:ACIU) with an “outperform” rating and price target of $18. The stock closed at $9.65 on Nov. 15. AC Immune develops medicines and diagnostic tools for...

Leerink Partners launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with an “outperform” rating and $20 price target. The stock closed at $10.84 on Nov. 15. Adamas applies its drug delivery technology to improve...

Leerink Partners initiated coverage of Intra-Cellular Therapies (NASDAQ:ITCI) with an “outperform” rating and $27 price target. The stock closed at $15.86 on Nov. 14. Intra-Cellular is focused on development of...

Leerink Partners upgraded Mersana Therapeutics (NASDAQ:MRSN) to “outperform” from “market perform” but maintained its price target of $14, citing the stock’s valuation. It closed at $6.04 on Nov. 13. “We are upgrading...

Leerink Partners launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and $50 price target. The stock closed at $36.90 on Nov. 13. Biohaven is focused on a range of neurological...